⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16225157 | 0.81 | — | — | |
| SCHEMBL791112 | 0.77 | — | — | |
| SCHEMBL13175805 | 0.76 | — | — | |
| SCHEMBL12172360 | 0.71 | — | — | |
| SCHEMBL17151222 | 0.71 | — | — | |
| SCHEMBL24837088 | 0.71 | — | — | |
| SCHEMBL20157698 | 0.71 | — | — | |
| SCHEMBL2335288 | 0.71 | — | — | |
| SCHEMBL20157697 | 0.71 | — | — | |
| SCHEMBL11707194 | 0.70 | GRIN2D (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036680-A | Anti-fibrotic pyridones | 英特穆恩公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4739685-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-3762377-B1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | UNIV CORNELL (US) | 2025-08-20 | — | — | EP | disclosed |
| US-RE50527-E1 | Covalent inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025124544-A1 | 3,4-DIHYDRO-2H-BENZO[B][1,4]DIOXEPANE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 华润医药研究院（深圳）有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025008061-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-119192137-A | Inhibition of human integrin alpha4β7 | 莫菲克医疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2296653-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | Intermune, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009149188-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149188-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-10 | — | — | WO | disclosed |